Clinical Trials Browser

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03386617 2026-03-04

AKY15-HK-301_NEPA Study

Phase 2 Active not recruiting

55 enrolled

Breast

Breast Neoplasms

NCT06844669 2026-03-03

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Phase 2 Active not recruiting

7 enrolled

Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

186 enrolled

Breast

Breast Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast

Breast Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2 Active not recruiting

28 enrolled

Breast

Breast Neoplasms

NCT05721248 2026-02-20

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Phase 2 Active not recruiting

82 enrolled

Breast

Breast Neoplasms

NCT02927912 2026-02-17

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Phase 2 Active not recruiting

108 enrolled

Breast

Breast Neoplasms

NCT03587740 2026-02-17

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

82 enrolled

Breast

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

333 enrolled

Breast

Breast Neoplasms, Recurrence

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

200 enrolled

Breast

Breast Neoplasms

NCT06068985 2026-02-12

CHERRY-PICK

Phase 2 Active not recruiting

63 enrolled

Breast

Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast

Breast Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast

Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03624543 2026-01-30

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Phase 2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms

NCT01984138 2026-01-28

REVIVE

Phase 2 Active not recruiting

33 enrolled

Breast

Breast Neoplasms

NCT04316117 2026-01-26

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Phase 2 Active not recruiting

138 enrolled

Breast

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast

Breast Neoplasms

NCT04568616 2026-01-20

NAOMI

Phase 2 Active not recruiting

178 enrolled

Breast

Breast Neoplasms

NCT04576455 2026-01-16

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase 2 Active not recruiting

303 enrolled 23 charts

Breast

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2 Active not recruiting

90 enrolled

Breast

Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Phase 2 Active not recruiting

23 enrolled

Breast

Breast Neoplasms

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast

Breast Neoplasms

NCT02912312 2026-01-07

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

Phase 2 Active not recruiting

805 enrolled

Breast

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Active not recruiting

8 enrolled

Breast

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Phase 2 Active not recruiting

140 enrolled

Breast

Breast Neoplasms

NCT01196936 2026-01-05

LDTam

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast

Breast Neoplasms

NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Phase 2 Active not recruiting

114 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT03393845 2026-01-02

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Phase 2 Active not recruiting

47 enrolled

Breast

Breast Neoplasms

NCT04141449 2025-12-31

Potlako+

Phase 2 Active not recruiting

874 enrolled

BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Acquired Immunodeficiency Syndrome, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Neoplasms, Vulvar Neoplasms

NCT05305365 2025-12-23

Study Assessing QBS72S For Treating Brain Metastases

Phase 2 Active not recruiting

21 enrolled

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms, Meningeal Neoplasms

NCT05069038 2025-12-22

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Phase 2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Phase 2 Active not recruiting

35 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01245712 2025-12-17

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Phase 2 Active not recruiting

200 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02755896 2025-12-15

Trial to Compare Radiation Fibrosis With Five Versus Three Fractions

Phase 2 Active not recruiting

350 enrolled

Breast

Breast Neoplasms

Clinical Trials

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

CARABELA

TUXEDO-3

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

FELINE

SABINA

TUXEDO-4

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

TELESCOPE

STARTRK-2

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

AKY15-HK-301_NEPA Study

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Opti-HER2

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

PETREMAC

CHERRY-PICK

Next MONARCH 1

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

REVIVE

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

NAOMI

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

MK-7119-001

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

LDTam

Olaparib In Metastatic Breast Cancer

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Potlako+

Study Assessing QBS72S For Treating Brain Metastases

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

Trial to Compare Radiation Fibrosis With Five Versus Three Fractions